European Perspective on Multiple Myeloma Treatment Strategies in 2014
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients. In addition, nowadays it is possible to categorize patients more precisely into different risk groups, thus allowing the evaluation of therapies in different settings and enabling a better comparison of results across trials. Here, we review the evidence from clinical studies, which forms the basis for our recommendations for the management of patients with myeloma. Treatment approaches depend on “fitness,” with chronological age still being an important discriminator for selecting therapy. In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option. Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency, and a decision regarding post-ASCT therapy should only be made after detailed discussion of the pros and cons with the individual patient. Two- and three-drug combinations are recommended for patients not eligible for transplantation. Treatment should be administered for at least nine cycles, although different durations of initial therapy have only rarely been compared so far. Comorbidity and frailty should be thoroughly assessed in elderly patients, and treatment must be adapted to individual needs, carefully selecting appropriate drugs and doses. A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Self-citationHDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Self-citationSonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Self-citationLenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationA Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Self-citationDhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515239 · Cited by 192
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Cited by
Engelhardt, M., Domm, A.-S., Dold, S. M., Ihorst, G., Reinhardt, H., Zober, A., Hieke, S., Baayen, C., Müller, S. J., Einsele, H., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.162693 · Cited by 274
Self-citationFrontline therapy of multiple myeloma
Moreau, P., Attal, M., & Facon, T. (2015) · Blood · doi:10.1182/blood-2014-09-568915 · Cited by 244
Self-citationRaje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Self-citationThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
Bieghs, L., Johnsen, H. E., Maes, K., Menu, E., Van Valckenborgh, E., Overgaard, M. T., Nyegaard, M., Conover, C. A., Vanderkerken, K., & De Bruyne, E. (2016) · Oncotarget · doi:10.18632/oncotarget.8982 · Cited by 61
A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma
Rajeev Krishnan, S., De Rubis, G., Suen, H., Joshua, D., Lam Kwan, Y., & Bebawy, M. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0304-7 · Cited by 34
Metadata
- Authors
- Ludwig, H., Sonneveld, P., Davies, F., Bladé, J., Boccadoro, M., Cavo, M., Morgan, G., de la Rubia, J., Delforge, M., Dimopoulos, M., Einsele, H., Facon, T., Goldschmidt, H., Moreau, P., Nahi, H., Plesner, T., San-Miguel, J., Hajek, R., Sondergeld, P., & Palumbo, A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-25
- Volume
- 19
- Issue
- 8
- Pages
- 829-844
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2138389659
- Cited by
- 99
- References
- 8
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European Perspective on Multiple Myeloma Treatment Strategies in 2014. https://app.cochat.ai/papers/10.1634/theoncologist.2014-0042
- The paper
- Ludwig, H., Sonneveld, P., Davies, F., Bladé, J., Boccadoro, M., Cavo, M., Morgan, G., de la Rubia, J., Delforge, M., Dimopoulos, M., Einsele, H., Facon, T., Goldschmidt, H., Moreau, P., Nahi, H., Plesner, T., San-Miguel, J., Hajek, R., Sondergeld, P., & Palumbo, A. (2014). European Perspective on Multiple Myeloma Treatment Strategies in 2014. The Oncologist. https://doi.org/10.1634/theoncologist.2014-0042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.